The effects of two types of renin-angiotensin system inhibitors on the hypertension induced by new pressor protein associated with beta-factor XIIa in rats

Akbar Pejhan , Ali Gohari, Mohammad Hassan Rakhshani, Peter C. Papageorgiou, Muhammad Ibrar Mustafa, Rahim Golmohammadi

Abstract


Background and purpose: New pressor protein (NPP) is a human plasma enzyme, which is structurally related to the beta-fragment of activated factor XІІ. The present study aimed to compare the effects of angiotensin converting enzyme inhibitors (captopril) and angiotensin type 1 receptor blocker (losartan) on the hypertension induced by NPP injection in normal (sham-2NX) and bilaterally nephrectomized rats (2NX).

Experimental approach: In total, 60 male Wistar rats were sham operated or bilaterally nephrectomized under anesthesia. After 24 h of anesthesia with Inactin® (100 mg/kg), their systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) were measured before and after the intravenous administration of captopril, losartan, and NPP.

Findings / Results: In the sham-2NX group, after NPP injection, changes were observed in SBP (145.99 ± 3.6 mmHg), DBP (93.9 ± 3.87 mmHg), and HR (400.29 ± 12.78 bpm). In the captopril group, SBP and DBP had no significant changes, while HR increased significantly (P = 0.001). In the losartan group, SBP and DBP decreased (P = 0.001 and P = 0.000, respectively), while HR had no significant changes. In the 2NX group, after NPP injection, changes were denoted in SBP (127.89 ± 9.03 mmHg), DBP (65.86 ± 5.69 mmHg), and HR (333.35 ± 11.47 bpm). In addition, captopril injection increased DBP (P = 0.016) and HR (P = 0.036) in response to NPP injection, while losartan injection had no significant effects in this regard.

Conclusion and implications: It could be concluded that losartan could improve hypertension in normal rats, while captopril deteriorated hypertension in bilaterally nephrectomized rats in this hypertension model.

 

 


Keywords


Captopril; Factor XII; Hypertension; Losartan; New pressor protein.

Full Text:

PDF

References


Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455): 217-223.

DOI: 10.1016/S0140-6736(05)17741-1.

GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L, Anderson HR, Bachman VF, Biryukov S, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(10010):2287-2323. DOI: 10.1016/S0140-6736(15)00128-2.

GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385(9963):117-171.

DOI: 10.1016/S0140-6736(14)61682-2.

Papageorgiou PC, Yeo EL, Backx PH, Floras JS. Activated plasma coagulation β-Factor XII-induced vasoconstriction in rats. Clin Sci (Lond). 2012;122(12):581-590.

DOI: 10.1042/CS20110517

Papageorgiou PC, Pourdjabbar A, Amfilochiadis AA, Diamandis EP, Boomsma F, Osmond DH. Are cardiovascular and sympathoadrenal effects of human 'new pressor protein' preparations attributable to human coagulation β-FXIIa? Am J Physiol Heart Circ Physiol. 2004;286(3):H837-846.

DOI: 10.1152/ajpheart.00693.2003.

Papageorgiou PC, Chan CT, Yeo EL, Backx PH, Floras JS. Coagulation factor XIIa-kinin-mediated contribution to hypertension of chronic kidney disease. J Hypertens. 2014;32(7):1523-1533.

DOI: 10.1097/HJH.0000000000000192.

Pearl RJ, Papageorgiou PC, Goldman M, Amfilochiadis AA, Boomsma F, Rojkjaer R, et al. Possible role of 'new pressor protein' in hypertensive anephric hemodialysis patients. Pediatr Nephrol. 2003;18(10):1025-1031.

DOI: 10.1007/s00467-003-1246-6.

Abbasi S, Yousefi G, Ansari AA, Mohammadi-Samani S. Formulation and in vitro evaluation of a fast-disintegrating/sustained dual release bucoadhesive bilayer tablet of captopril for treatment of hypertension crises. Res Pharm Sci. 2016;11(4):274-283.

DOI: 10.4103/1735-5362.189284.

Janahmadi Z, Nekooeian AA, Mozafari M. Hydroalcoholic extract of Allium eriophyllum leaves attenuates cardiac impairment in rats with simultaneous type 2 diabetes and renal hypertension. Res Pharm Sci. 2015;10(2):125-133.

Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP, Crooke RM. Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury. Hypertension. 2017;70(3):566-576.

DOI: 10.1161/HYPERTENSIONAHA.117.09755.

Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2014;(8):1-49.

DOI: 10.1002/14651858.CD009096.pub2.

Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol. 2018;71(13):1474-1482.

DOI: 10.1016/j.jacc.2018.01.058.

Pejhan A, Papageorgiou PC, Osmond D. The effects of human 'new pressor protein' and coagulation factor XIIa on blood pressure and heart rate in bilaterally nephrectomized rats. Iran J Med Sci. 2007;32(1): 22-27.

Almeida LF, Tofteng SS, Madsen K, Jensen BL. Role of the renin-angiotensin system in kidney development and programming of adult blood pressure. Clin Sci (Lond). 2020;134(6):641-656. DOI: 10.1042/CS20190765.

Aldehni F, Tang T, Madsen K, Plattner M, Schreiber A, Friis UG, et al. Stimulation of renin secretion by catecholamines is dependent on adenylyl cyclases 5 and 6. Hypertension. 2011;57(3):460-468.

DOI: 10.1161/HYPERTENSIONAHA.110.167130.

Papageorgiou PC, Simos D, Boomsma F, Rojkjaer R, Osmond DH. Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIa. Can J Cardiol. 2009;25(4):e100-e108.

DOI: 10.1016/s0828-282x(09)70067-4.

Simos D, Boomsma F, Osmond DH. Human coagulation factor XII-related 'new pressor protein': role of PACAP in its cardiovascularand sympathoadrenal effects. Can J Cardiol. 2002;18(10):1093-1103.

Amfilochiadis AA, Papageorgiou PC, Kogan N, Boomsma F, Osmond DH. Role of bradykinin B2-receptor in the sympathoadrenal effects of 'new pressor protein' related to human blood coagulation factor XII fragment. J Hypertens. 2004;22:1173-1181.

DOI: 10.1097/00004872-200406000-00019.

Pejhan A, Papageorgiou PC, Osmond DH. Role of bradykinin in the actions of 'new pressor protein' related to human plasma βFXIIa. Koomesh. 2004;6(1):21-30.

Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:1-8.

DOI: 10.1136/bmj.k4209.

Kmietowicz Z. ACE inhibitors are linked to increased lung cancer risk, study finds. BMJ. 2018;363:k4471. DOI: 10.1136/bmj.k4471.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.